Nanobiotix updates on JNJ-1900 (NBTXR3) trials, FDA-cleared protocol change, and cash into 2029
New Phase 1 lung cancer data, early CONVERGE efficacy signals, and a NANORAY-312 protocol amendment accompanied a first half 2026 financial report showing €110.9 million in cash.
SEC filing